MedTrace Logo

A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor

NCT03049774 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2017-02-10

No results posted yet for this study

Summary

The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include May 8th of 2008 to december 31st of 2016.

Conditions

  • Chemotherapy-induced Thrombocytopenia

Sponsors & Collaborators

  • Angde Biotech Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2017-08-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03049774 on ClinicalTrials.gov